secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001724521-24-000136
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus reports Q2 2024 net loss $93M, cash $1.0B; casdatifan data due Q4
-----------------------------------------------------------------------

- Revenue $39M (up from $29M in Q2 2023); net loss $93M vs $75M year-over-year.
- Cash, cash equivalents and marketable securities $1.0B, sufficient into 2027; expects $885-925M by year-end 2024.
- Casdatifan 100mg ccRCC expansion ORR data expected Q4 2024; PEAK-1 Phase 3 study start H1 2025.
- STAR-221 (domvanalimab+chemo) completed enrollment; STAR-121 (NSCLC) expected to complete enrollment in 2024.
- Taiho exercised option for quemliclustat in Japan/Asia; Phase 3 PRISM-1 pancreatic cancer to start early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000136/0001724521-24-000136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452124000136/rcus-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001724521-24-000136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer